key: cord-0998987-8ptar0fk authors: Peluso, Michael J; Dee, Lynda; Shao, Shirley; Taylor, Jeff; Campbell, Danielle; Collins, Simon; Gandhi, Monica; Johnston, Rowena; Deeks, Steven G; Sauceda, John A; Dubé, Karine title: Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach date: 2020-08-25 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1260 sha: 166ae6b05804cec977acb9b74265edcc6d9e9e91 doc_id: 998987 cord_uid: 8ptar0fk Efforts to recognize and minimize the risk to study participants will be necessary to safely and ethically resume scientific research in the context of the ongoing SARS-CoV-2 pandemic. These efforts are uniquely challenging in the context of HIV-cure clinical trials, which often involve complex experimental therapy regimens and perhaps analytic treatment interruption (ATI), in which participants pause antiretroviral therapy (ART). In this viewpoint, we discuss our approach to re-opening an HIV-cure trial in this context, with a focus on key considerations regarding study design, informed consent and participant education, and study implementation. These recommendations might be informative to other groups seeking to resume HIV-cure research in settings similar to ours. The SARS-CoV-2 pandemic has had a major impact on research operations worldwide. As shelter-in-place guidelines were implemented throughout early 2020, many centers suspended research efforts to protect study participants and research staff while the scientific and medical communities raced to understand this novel infection. Since that time, significant progress has been made in understanding the transmission, prevention, and management of SARS-CoV-2 infection and its associated illness, COVID-19 [1] [2] [3] [4] [5] [6] . Just as the pandemic has taken a toll on patients without COVID-19 who delay or defer life-saving medical care [7] , there is growing recognition that continued deferment of participant-based research has the potential to set back scientific progress and the advancement of health. For these reasons, institutions are beginning to relax SARS-CoV-2 restrictions while implementing new precautions based on our now-substantial knowledge of routes of SARS-CoV-2 transmission to maximize safety. Recognizing and mitigating the risk of SARS-CoV-2 infection is a critical step in ensuring that research studies can be conducted safely and ethically in the context of the ongoing pandemic. Safety considerations are important in the context of HIV research studies, particularly trials of investigational agents that are meant to achieve sustained antiretroviral treatment (ART)free suppression of HIV infection [8] . There are several reasons why this is the case. First, the level of intensity of such trials is likely to place participants at elevated risk for acquiring SARS-CoV-2 by increasing the number of potential exposure events due to the high frequency of study visits. Second, the impact of the interaction between HIV and SARS-CoV-2 co-infection remains incompletely understood, particularly in people living with HIV (PLWH) A c c e p t e d M a n u s c r i p t who have additional comorbidities associated with increased COVID-19 severity [9] [10] [11] [12] . The risk is likely to be even more significant when comorbidities are incompletely controlled [13] . Third, such studies often require an analytic treatment interruption (ATI) in which participants discontinue HIV medications under close medical supervision to determine the effect of interventions aimed at ART-free suppression [8, 14] . Participants are expected to experience HIV rebound during the ATI, and the impact of SARS-CoV-2 infection in PLWH off ART remains a major research question [10] . In light of these considerations, we developed and implemented recommendations prior to re-opening a clinical trial that may be used as a model for similar HIV cure-related research operations that are attempting to open in the context of the ongoing SARS-CoV-2 pandemic. Our goal was to determine how to best operationalize an ATI in the era of COVID-19 and generate an actionable plan that would allow this clinical trial to safely resume. Our process involved close multi-disciplinary consultation between the biomedical study team, our community advisory boards including racially, ethnically, and geographically diverse community members, and socio-behavioral scientists. The multi-disciplinary approach outlined here was developed over a series of meetings during which the goal was to minimize the risk of SARS-CoV-2 acquisition and severe COVID-19 disease while empowering research participants to make informed decisions about their involvement in the study. A c c e p t e d M a n u s c r i p t We began by defining three general principles to guide the research team during the study period: (1) We believe in the ongoing value of HIV cure-related research notwithstanding the challenges posed by the SARS-CoV-2 pandemic. Our team articulated the position that engagement in studies employing ATIs is acceptable in cases in which the research goal is considered essential and a sufficient risk mitigation plan can be implemented. (2) We commit to reviewing all emerging data on general and HIV-specific risks of SARS-CoV-2 infection, as well as local epidemiology and public health recommendations during the course of the study. This commitment acknowledges that recommendations related to SARS-CoV-2 prevention and treatment are likely to evolve over time. As a result, the team must be willing to update study procedures according to emerging findings and recommendations, with the overall goal of risk mitigation and rigorous participant throughout the study. (3) We seek to balance the dual considerations of protocol-defined exclusions and robust informed consent regarding study participation risk. This was most clearly illustrated by efforts to implement both protocol-defined restrictions based on the current understanding of COVID-19 risk with efforts to empower participants to make informed decisions about the acceptability of such risks in individual cases. Following these principles, our team sought to answer critical questions related to study design, informed consent and participant education, and study implementation ( Table 1) . A c c e p t e d M a n u s c r i p t The goal of this effort was to identify and mitigate risk throughout the study, as summarized in Figure 1A -B. We began by asking the question: "Should this study be re-opened during the SARS-CoV-2 pandemic?" To address this question, the study team and community advisory board convened a meeting and discussed whether the scientific questions addressed by the trial were of sufficient importance to justify the potential for increased risk to study participants. This included discussion of the overall scientific value of the trial, the current risk-benefit assessment, and how this assessment might change if the study needed to be altered, paused, or halted in the future. We reached consensus that the study should proceed as long as an extensive risk mitigation plan could be implemented. Because the ATI in this study would occur 34 weeks after enrollment, we acknowledged that there would be insufficient information for participants to make an informed decision regarding the ATI at the time of the initial consent process. For this reason, we decided it would be necessary to allow participants to re-consent or opt out of the ATI based on an upto-date risk-benefit assessment in closer proximity to that stage of the study. This opportunity for re-assessment at the time of the ATI is likely to be critical for similar studies involving a delay between initial consent and treatment interruption, but may not be necessary when the ATI occurs in closer proximity to study enrollment. The decision was further informed by the study team's determination that important scientific questions could still be answered even in cases in which a participant who completed the study interventions A c c e p t e d M a n u s c r i p t declined to interrupt HIV medications. In cases in which these facts are not present, investigators may choose to postpone the start of the study until the end of the pandemic. We deliberated on whether to employ strict study exclusion criteria in the context of the SARS-CoV-2 pandemic. This included review of evidence regarding factors associated with elevated risk of adverse outcomes related to SARS-CoV-2 infection in general and/or in people with HIV [9, 10, 13, [15] [16] [17] , as well as acknowledgement that implementation of strict exclusions based on some factors (i.e., diabetes, hypertension, obesity) might preclude the eligibility of racial/ethnic minority populations who are disproportionately affected by HIV [18] [19] [20] . Thus, we adopted an approach that balanced strict exclusions versus more intensified exclusion thresholds that address safety concerns among those likely to be at the highest risk. In addition, we ensured that our informed consent process clearly describes the increased risk of participation. Our pre-existing protocol exclusion criteria would exclude candidates with potentially severe COVID-19 outcomes (e.g., advanced age greater than 65 years old, pre-existing cardiovascular, kidney, or liver disease) based on previous ATI study norms. In addition, we added exclusions based on severe or uncontrolled diabetes, uncontrolled hypertension, obesity, and active tobacco smoking or vaping ( Table 2) . We balanced these exclusions by allowing enrollment of individuals with less severe manifestations of these comorbidities, and in such individuals, chose to focus on strengthening risk mitigation strategies and the informed consent process regarding COVID-19 and other potential trial risks. A c c e p t e d M a n u s c r i p t We decided to strengthen the informed consent process with acknowledgement of the potential for increased risk of exposure to SARS-CoV-2 and/or severity of illness if infection occurs, as well as the acknowledgement that there are limited data on the impact of infection on PLWH in the absence of ART. Sample consent language is available in Appendix I. The informed consent process will include intense personal, case-by-case counseling, as well as the acknowledgement that there will be unknown risks during the study. To account for emerging scientific information around SARS-CoV-2, COVID-19, and HIVas well as evolving standards of prevention and treatmentwe plan to re-consent trial participants at key time points in the study based on updated risk information and scientific evidence. The informed consent form and handouts provided to study participants will be updated regularly based on emerging data and will include additional links to websites where up-to-date information can be found. To further strengthen the informed consent process, we prepared written materials for trial participants to summarize COVID-19 risk and risk mitigation strategies to be employed during the study (Appendix II -III). To ensure participants are adequately informed and counseled during the study, we are also making additional study staff available to discuss COVID-19-related risks throughout the study. A c c e p t e d M a n u s c r i p t Since an important risk from participation in the study was considered to be the frequency of in-person trial visits at the study site, we decided on a three-fold strategy to mitigate this risk. First, we will offer telemedicine visits and/or home phlebotomy when feasible and desired. Second, we will maximize travel safety by incentivizing self-driving when possible, paying for private rideshare or taxi services to minimize the need for public transportation, and offering face masks to participants to use during travel. Third, we will maximize safety at the study site by following up-to-date medical center policies ( Table 3) . These include pre-visit telephone health screening (e.g., symptom assessment prior to each visit), in-person health screening (e.g., temperature checks) required to gain access to the research center, physical distancing while at the research center (e.g., remaining six feet apart), and masking during all study interactions. Another important study design issue that emerged was whether to modify the frequency of HIV viral load monitoring during the ATI. Balancing the need for more intensive monitoring versus the risk of in-person attendance at the research site, we decided to maintain the same frequency of HIV viral load monitoring as before the SARS-CoV-2 pandemic in an effort to ensure participant safety. This aspect of the pandemic further underscores the need to develop and validate a reliable home-based viral load test for future remote monitoring during ATIs. Such an assay would greatly improve the ability of research teams to perform remote visits during the treatment interruption. A c c e p t e d M a n u s c r i p t Because of the potential combined effects of ATI and SARS-CoV-2 infection on lymphocyte populations [10, 21] , we also discussed the need for frequent CD4+ T cell count monitoring during the study. In our study, this parameter is measured at each visit, including weekly monitoring during the first 24 weeks of the ATI; regardless of plasma HIV RNA levels, treatment will be re-initiated if the CD4+ T cell count demonstrates a sustained decreased below 350 cells/uL. Other studies that do not otherwise require such intensive CD4+ T cell monitoring might consider doing so during the SARS-CoV-2 pandemic. As with viral monitoring, this also comes with the need of balancing intensive monitoring against the risk of in-person attendance. There was consensus that due to the nature of the experimental therapies and ATI, the trial needed to include SARS-CoV-2 testing for both asymptomatic and symptomatic participants. To balance participant safety and minimize burden, we identified key trial time points for SARS-CoV-2 testing of asymptomatic participants. This included testing prior to the start of the immune-based interventions, prior to the start of the ATI, and every 4 weeks during the ATI period. In addition, SARS-CoV-2 testing will be performed upon participant request (e.g., opt-in procedure due to possible known exposure). Asymptomatic participants will also have the option to opt-out of testing to reduce burden and discomfort. To further minimize the burden to participants, our trial team implemented a plan to provide on-site testing free of cost. We will also provide participants with written COVID-19 testing location information if they wish to be tested at other sites. A c c e p t e d M a n u s c r i p t We formulated a response plan for situations related to COVID-19 symptoms or confirmed diagnosis of SARS-CoV-2 infection. Participants who report symptoms potentially attributable to COVID-19 will receive testing center navigation assistance, which in most cases will include connection to testing through primary care providers or the local Department of Public Health. Study visits will be deferred at the discretion of the Principal Investigator until negative testing is confirmed or symptoms resolve. We will also follow up-to-date medical center policies regarding the timing of visits following development of symptoms. In the event that a participant tests positive for SARS-CoV-2, the response will depend upon the stage of the protocol in which the positive test occurs. During the intervention portion of the study, upcoming interventions will be delayed until deemed safe by the Principal Investigator. In general, this will be for a period of 14 days, according to the current guidance at the time of diagnosis. During the ATI period, the Principal Investigator will consult with the study participant regarding ongoing participation in the ATI or ART re-initiation. Study continuation will be based upon the current guidance at the time, and will consider factors such as (1) A c c e p t e d M a n u s c r i p t Finally, we considered a situation in which the broader local epidemic worsens, given the challenges in predicting epidemiologic trends over the full duration of the study. We acknowledged that once the trial is underway, there will need to be ongoing risk assessment in consultation with the community advisory board and the trial's safety monitoring committee, which has the capacity to serve as an external advisory body to make recommendations regarding continuing, pausing, or halting the study. This might include pausing enrollment or, if necessary, postponing certain study interventions if determined to not affect participant safety or compromise the scientific integrity of the study. In cases in which the local epidemiology changes and shelter-in-place recommendations are initiated, we plan to convene the safety monitoring committee to determine whether the study interventions and/or ATI should be delayed or halted for all participants. While one of our primary efforts is to provide education to participants on the risks associated with COVID-19, we acknowledge the complexity of both the study and the SARS-CoV-2 pandemic. For this reason, in addition to providing trial-related resources to participants, we also encourage them to engage with their primary care and/or HIV clinician as an external advisor throughout the study. This model has served us and our study volunteers well over decades of HIV research, and includes encouraging the participant to discuss the study's risk-benefit ratio before enrollment and throughout their participation, as well as making all study-related laboratory results available to the primary clinician. In the case of the SARS-CoV-2 pandemic, this provider represents an external party invested in the participant's well-being who can provide advice on ongoing participation in the context of both clinical and local epidemiologic knowledge. In other settings, a community health worker or other community advisor might serve in a similar role. A c c e p t e d M a n u s c r i p t Although hypothetical, we also discussed our approach should a SARS-CoV-2 vaccine become available during the trial period. Participants in our study would be excluded from participating in another concurrent trial of a SARS-CoV-2 vaccine due to a combination of scientific and safety issues. However, should a SARS-CoV-2 vaccine become available and approved during the course of our study, we would encourage participants who wished to receive the vaccine to do so; study measurements would be adjusted accordingly. In addition, our socio-behavioral sub-study allows the trial team to track COVID-19 as an emergent theme. Of note, local epidemiologic trends mirror state-and country-level data demonstrating higher rates of SARS-CoV-2 infection among Black and Latinx populations. Factors affecting the participation of these groups and other marginalized populations (i.e., women, transgender individuals, HIV serodiscordant/mixed-status couples) in HIV-cure related research are not well-understood. Given this, and the study team's efforts at broad inclusion, our study could be among the first to capture rigorous data from such populations participating in HIV cure-related research involving an ATI during the SARS-CoV-2 pandemic. We are also working with trial participants to be responsive to their needs and concerns throughout the trial [22] .The SARS-CoV-2 plan supplements our other risk mitigation strategies for HIV transmission risk mitigation during the ATI [23] . A c c e p t e d M a n u s c r i p t Our COVID-19 risk mitigation plan was developed in a region with ample testing capacity and that currently has a relatively small epidemic. Other clinical research sites implementing ATI trials will need to fully consider their local epidemiologic situation. We also recognize the risk of acquiring COVID-19 or developing severe outcomes may differ between various population groups, particularly racial/ethnic minority populations in the U.S. [24] . We are actively monitoring emerging SARS-CoV-2 scientific findings during the study and updating our trial protocol and informed consent as needed. In addition to the risks it poses to health worldwide, the SARS-CoV-2 pandemic is a major threat to the scientific progress that is necessary to drive forward research priorities such as the HIV cure agenda. In the setting of rapid developments in understanding the transmission, pathogenesis, and prevention of SARS-CoV-2 since the beginning of the pandemic, our multidisciplinary team has chosen to follow a harm or risk reduction approach regarding HIV cure-related studies including ATIs during the COVID-19 pandemic. We will continue to follow universal precautions for SARS-CoV-2, emerging participant risk level data, local COVID-19 epidemiology, and public health recommendations. At this time, we believe our multi-pronged mitigation and rigorous informed consent approaches provide reasonable methods to limit evolving SARS-CoV-2 infection risk while allowing scientific progress in the search towards sustained ART-free suppression of HIV. A c c e p t e d M a n u s c r i p t M a n u s c r i p t Is the research question of sufficient importance that potential increased risks to participants is acceptable? Should the study be implemented during the SARS-CoV-2 pandemic? Are there structural changes to the study that might minimize risks to participants? Should exclusion criteria be updated to minimize participant risk? What should be the frequency of COVID-19 testing during the study? What should be the frequency of HIV viral load monitoring during the ATI? What should be the frequency of CD4+ T cell monitoring during the ATI? How should study risks related to SARS-CoV-2 be described in the informed consent form? How can the study team ensure that participants are adequately informed and counseled about SARS-CoV-2-related risks during the study? How should the study team account for emerging scientific information around SARS-CoV-2, COVID-19 and HIV, and evolving standards of prevention and treatment during the study? Is there an independent clinician or health advisor with whom the participant can engage throughout the study? How can risks related to the frequency of in-person trial visits be minimized? What should SARS-CoV-2 standard of prevention precautions look like? What additional risk mitigation measures should be implemented around the ATI? What should happen if a participant has COVID-19-related symptoms? What should happen if a participant tests positive for SARS-CoV-2 during the study? What would happen if the local SARS-CoV-2 epidemic worsens? How can an independent body such as a Community Advisory Board or Safety Monitoring Committee be engaged to advise the study team during the study? How would the roll-out of multiple SARS-Cov2 vaccine trials or potential implementation of an efficacious and approved vaccine be handled during the study? Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US Lack of COVID-19 transmission on an international flight Respiratory virus shedding in exhaled breath and efficacy of face masks Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis Remdesivir for the Treatment of Covid-19 -Preliminary Report Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report The Untold Toll -The Pandemic's Effects on Patients without Covid-19 Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV OpenSAFELY: factors associated with COVID-19 death in 17 million patients How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies? COVID-19 in patients with HIV: clinical case series COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort Disproportionate burden of COVID-19 among racial minorities and those in congregate settings among a large cohort of people with HIV Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption Coronavirus Disease 2019 Case Surveillance -United States The authors would like to acknowledge the contributions of the amfAR and DARE Community Advisory Boards. This work was supported by funding from the National Institute for Allergy and Infectious A c c e p t e d M a n u s c r i p t